- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Cabozantinib Exposure Not Associated With PFS, But Is Linked With Higher AEs With Cabozantinib/Nivolumab in RCC
June 9th 2021, 8:20pm
Cabozantinib exposure was not significantly associated with progression-free survival but appeared to predict high rates of palmar-plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma treated with the frontline combination of cabozantinib and nivolumab.
Lenvatinib/Pembrolizumab Yields Survival Benefit in Advanced RCC Across IMDC Risk Groups
June 9th 2021, 6:17pm
The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.
Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC
June 9th 2021, 6:09pm
The combination of pembrolizumab and cabozantinib induced a response in more than half of patients with metastatic renal cell carcinoma at the recommended phase 2 dose with a manageable safety profile, meeting the primary end point of a phase 1/2 trial.
Lenvatinib Plus Toripalimab and Hepatic Arterial Infusion Chemotherapy May Represent a New First-Line Option in Advanced HCC
June 9th 2021, 5:14pm
The addition of toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses in patients with advanced hepatocellular carcinoma, and represents a potential new treatment option for patients in the first line setting.
Real-World Analysis on Second-Line Cetuximab in mCRC Reveals Factors Linked With Longer Time on Treatment, OS
June 9th 2021, 2:17pm
In patients with metastatic colorectal cancer who received cetuximab as a second-line therapy after irinotecan or oxaliplatin-based regimens have failed, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.
Addition of Abiraterone to ADT plus Docetaxel Yields Improvement in rPFS in De Novo mCSPC
June 9th 2021, 12:08pm
Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.
Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong
June 9th 2021, 12:00am
OncLive News Network: On Location at ASCO 2021
OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.
Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma
June 8th 2021, 11:00pm
The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Subsequent Therapy May Impact OS Outcomes With Frontline Lenvatinib/Everolimus in RCC
June 8th 2021, 10:35pm
Subsequent systemic therapies were found to impact overall survival outcomes with lenvatinib plus everolimus versus sunitinib in patients with advanced renal cell carcinoma who received treatment in the phase 3 CLEAR trial.
Dr. Markowski on the Safety and Efficacy of VERU-111 in mCRPC
June 8th 2021, 9:10pm
Mark Christopher Markowski, MD, PhD, discusses the safety and efficacy of VERU-111 in patients with metastatic castration-resistant prostate cancer.
Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma
June 8th 2021, 8:02pm
Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.
TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS
June 8th 2021, 7:25pm
The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
Pimitespib Doubles PFS in Advanced Refractory GIST
June 8th 2021, 6:25pm
The heat shock protein 90 inhibitor pimitespib led to a significant improvement in progression-free survival and prolongation in overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib.
Dr. Ramalingam on Updated Data With Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
June 8th 2021, 5:55pm
Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.
Teclistamab Demonstrates Encouraging Efficacy, Safety at the RP2D in Relapsed/Refractory Multiple Myeloma
June 8th 2021, 5:50pm
Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL
June 8th 2021, 5:45pm
C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Men With African Ancestry Less Likely to Receive Early Genomic Profiling in Prostate Cancer
June 8th 2021, 5:34pm
Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.
Alrizomadlin/Pembrolizumab Induces Early Efficacy in Unresectable Melanoma or Advanced Solid Tumors
June 8th 2021, 5:32pm
The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.
TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder Cancer
June 8th 2021, 4:39pm
Combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer.